Literature DB >> 21630295

Androgens repress expression of the F-box protein Skp2 via p107 dependent and independent mechanisms in LNCaP prostate cancer cells.

Jingting Jiang1, Yunqian Pan, Kevin M Regan, Changping Wu, Xueguang Zhang, Donald J Tindall, Haojie Huang.   

Abstract

BACKGROUND: Androgens control homeostasis of the normal prostate and growth of prostate cancer (PCa) through the androgen receptor (AR) by regulating gene networks involving in cell proliferation, differentiation, and survival. We demonstrated previously that expression of Skp2, a key protein regulating cell entry into the S phase, is inhibited by androgens in an AR-dependent manner (Oncogene, 2004; 23(12): 2161-2176). However, the underlying mechanism of this regulation is unknown.
METHODS: Using the LNCaP PCa cell line as a working model, the effect of androgens on the expression of Skp2 was examined by Western and Northern blot analyses. Cell cycle was measured by fluorescence-activated cell sorting (FACS). Gene transfection was performed by electroporation to manipulate the expression levels of proteins studied.
RESULTS: At physiological levels androgens markedly repressed Skp2 expression but slightly induced Skp2 expression at subphysiological levels. Androgens modestly decreased the stability of the Skp2 protein. Androgenic repression of Skp2 expression was completely abolished by E1A-mediated inactivation of pocket proteins including RB, p130, and p107. Moreover, ectopic expression of p107 inhibited Skp2 expression, and silencing of p107 partially blocked androgenic repression of Skp2.
CONCLUSIONS: Our data indicate that androgens repress Skp2 expression via p107-dependent and -independent pathways in PCa cells. These regulatory mechanisms may be targeted for the development of new therapeutics of androgen-refractory PCa.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21630295      PMCID: PMC4413901          DOI: 10.1002/pros.21430

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  29 in total

1.  Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence.

Authors:  Hui-Kuan Lin; Zhenbang Chen; Guocan Wang; Caterina Nardella; Szu-Wei Lee; Chia-Hsin Chan; Chan-Hsin Chan; Wei-Lei Yang; Jing Wang; Ainara Egia; Keiichi I Nakayama; Carlos Cordon-Cardo; Julie Teruya-Feldstein; Pier Paolo Pandolfi
Journal:  Nature       Date:  2010-03-18       Impact factor: 49.962

2.  SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27.

Authors:  A C Carrano; E Eytan; A Hershko; M Pagano
Journal:  Nat Cell Biol       Date:  1999-08       Impact factor: 28.824

3.  Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate.

Authors:  Eun-Hee Shim; Linda Johnson; Hye-Lim Noh; Yoon-Jung Kim; Hong Sun; Caroline Zeiss; Hui Zhang
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

Review 4.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.

Authors:  Howard I Scher; Charles L Sawyers
Journal:  J Clin Oncol       Date:  2005-11-10       Impact factor: 44.544

5.  Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation.

Authors:  Haojie Huang; Kevin M Regan; Fang Wang; Diping Wang; David I Smith; Jan M A van Deursen; Donald J Tindall
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-24       Impact factor: 11.205

6.  PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression.

Authors:  H Huang; J C Cheville; Y Pan; P C Roche; L J Schmidt; D J Tindall
Journal:  J Biol Chem       Date:  2001-08-08       Impact factor: 5.157

7.  The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression.

Authors:  Meletios Verras; Jane Lee; Hui Xue; Tzu-Huey Li; Yuzhuo Wang; Zijie Sun
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

8.  Androgens repress Bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cells.

Authors:  Haojie Huang; Ofelia L Zegarra-Moro; Douglas Benson; Donald J Tindall
Journal:  Oncogene       Date:  2004-03-18       Impact factor: 9.867

9.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Authors:  Michael Stanbrough; Glenn J Bubley; Kenneth Ross; Todd R Golub; Mark A Rubin; Trevor M Penning; Phillip G Febbo; Steven P Balk
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

10.  Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation.

Authors:  Takumi Kamura; Taichi Hara; Shuhei Kotoshiba; Masayoshi Yada; Noriko Ishida; Hiroyuki Imaki; Shigetsugu Hatakeyama; Keiko Nakayama; Keiichi I Nakayama
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-18       Impact factor: 11.205

View more
  11 in total

Review 1.  Skp2: a novel potential therapeutic target for prostate cancer.

Authors:  Zhiwei Wang; Daming Gao; Hidefumi Fukushima; Hiroyuki Inuzuka; Pengda Liu; Lixin Wan; Fazlul H Sarkar; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2011-09-22

2.  Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein.

Authors:  Shuai Gao; Yanfei Gao; Housheng Hansen He; Dong Han; Wanting Han; Amy Avery; Jill A Macoska; Xiaming Liu; Sen Chen; Fen Ma; Shaoyong Chen; Steven P Balk; Changmeng Cai
Journal:  Cell Rep       Date:  2016-10-18       Impact factor: 9.423

3.  Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer.

Authors:  Wanting Han; Mingyu Liu; Dong Han; Anthia A Toure; Muqing Li; Anna Besschetnova; Zifeng Wang; Susan Patalano; Jill A Macoska; Hung-Ming Lam; Eva Corey; Housheng Hansen He; Shuai Gao; Steven P Balk; Changmeng Cai
Journal:  Mol Ther       Date:  2022-02-02       Impact factor: 12.910

4.  Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.

Authors:  Michael D Nyquist; Alexandra Corella; Ilsa Coleman; Navonil De Sarkar; Arja Kaipainen; Gavin Ha; Roman Gulati; Lisa Ang; Payel Chatterjee; Jared Lucas; Colin Pritchard; Gail Risbridger; John Isaacs; Bruce Montgomery; Colm Morrissey; Eva Corey; Peter S Nelson
Journal:  Cell Rep       Date:  2020-05-26       Impact factor: 9.423

5.  Melanoma antigen-A11 regulates substrate-specificity of Skp2-mediated protein degradation.

Authors:  Shifeng Su; Xiaoyu Chen; Jiang Geng; John T Minges; Gail Grossman; Elizabeth M Wilson
Journal:  Mol Cell Endocrinol       Date:  2016-10-06       Impact factor: 4.102

6.  Episode-like pulse testosterone supplementation induces tumor senescence and growth arrest down-modulating androgen receptor through modulation of p-ERK1/2, pARser81 and CDK1 signaling: biological implications for men treated with testosterone replacement therapy.

Authors:  Giovanni Luca Gravina; Francesco Marampon; Patrizia Sanità; Claudio Festuccia; Chiara Forcella; Luca Scarsella; Anna Jitariuc; Antonella Vetuschi; Roberta Sferra; Alessandro Colapietro; Eleonora Carosa; Susanna Dolci; Andrea Lenzi; Emmanuele A Jannini
Journal:  Oncotarget       Date:  2017-11-30

7.  Discovery proteomics defines androgen-regulated glycoprotein networks in prostate cancer cells, as well as putative biomarkers of prostatic diseases.

Authors:  Jordy J Hsiao; Melinda M Smits; Brandon H Ng; Jinhee Lee; Michael E Wright
Journal:  Sci Rep       Date:  2021-11-15       Impact factor: 4.379

8.  Skp2 and its emerging role in the pathogenesis of systemic malignancies besides breast carcinomas.

Authors:  Shailendra Kapoor
Journal:  Front Oncol       Date:  2012-10-16       Impact factor: 6.244

9.  Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells.

Authors:  D Sun; R Layer; A C Mueller; M A Cichewicz; M Negishi; B M Paschal; A Dutta
Journal:  Oncogene       Date:  2013-03-18       Impact factor: 9.867

Review 10.  Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.

Authors:  Osama S Mohammad; Michael D Nyquist; Michael T Schweizer; Stephen P Balk; Eva Corey; Stephen Plymate; Peter S Nelson; Elahe A Mostaghel
Journal:  Cancers (Basel)       Date:  2017-12-06       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.